A5202: A PHASE III TRIAL OF OPEN-LABEL EFAVIRENZ OR ATAZANAVIR WITH RITONAVIR

A5202：开放标签依非韦伦或阿扎那韦联合利托那韦的 III 期试验

• 批准号: 7719360
• 负责人: PAUL SAX
• 金额: $ 0.48万
• 依托单位: BRIGHAM AND WOMEN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-04-01 至 2008-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7719360
• 关键词: Anti-HIV Agents; Atazanavir; Computer Retrieval of Information on Scientific Projects Database; Drug Combinations; Funding; Grant; Institution; Label; Phase; Purpose; Research; Research Personnel; Resources; Ritonavir; Safety; Source; United States National Institutes of Health; compare effectiveness; efavirenz

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of the study is to compare the effectiveness, safety, and tolerability of anti-HIV drug combinations.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 该研究的目的是比较抗HIV药物组合的有效性、安全性和耐受性。